Cargando…

Switching from glargine+insulin aspart to glargine+insulin aspart 30 before breakfast combined with exercise after dinner and dividing meals for the treatment of type 2 diabetes patients with poor glucose control – a prospective cohort study

BACKGROUND: This study aimed to examine the switch from glargine+once daily insulin aspart (1 + 1 regimen) to glargine+insulin aspart 30 before breakfast combined with exercise and in patients with type 2 diabetes mellitus (T2DM) with poorly controlled blood glucose levels. METHODS: Consecutive pati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Jing, Wang, Liming, Chen, Fen, Xia, Dongxia, Miao, Lingling
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6167858/ https://www.ncbi.nlm.nih.gov/pubmed/30285711 http://dx.doi.org/10.1186/s12902-018-0297-4

Ejemplares similares

Protocol to Assess the Biological Activity of Insulin Glargine, Insulin Lispro, and Insulin Aspart In Vitro
por: Garige, Mamatha, et al.
Publicado: (2023)

Differences in metabolic and mitogenic signalling of insulin glargine and insulin aspart B10 in rats
por: Tennagels, N., et al.
Publicado: (2013)

Cost comparison of insulin glargine with insulin detemir in a basal-bolus regime with mealtime insulin aspart in type 2 diabetes in Germany
por: Pscherer, Stefan, et al.
Publicado: (2010)

A Randomized Clinical Trial of Insulin Glargine and Aspart, Compared to NPH and Regular Insulin in Children with Type 1 Diabetes Mellitus
por: Rostami, Parastoo, et al.
Publicado: (2014)

Insulin glargine overdose
por: Doğan, Fatma Sarı, et al.
Publicado: (2012)

Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus
por: Linnebjerg, Helle, et al.
Publicado: (2016)

Safety, Immunogenicity, and Glycemic Control of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Also Using Insulin Glargine: 12-Month Results from the GEMELLI 1 Trial
por: Garg, Satish K., et al.
Publicado: (2020)

Insulin glargine and the risk of cancer
por: Ahmed, FA
Publicado: (2010)

Comparison of continuous subcutaneous insulin infusion and insulin glargine-based multiple daily insulin aspart injections with preferential adjustment of basal insulin in patients with type 2 diabetes
por: GAO, GUAN-QI, et al.
Publicado: (2014)

Comparison of a Multiple Daily Insulin Injection Regimen (Glargine or Detemir Once Daily Plus Prandial Insulin Aspart) and Continuous Subcutaneous Insulin Infusion (Aspart) in Short-Term Intensive Insulin Therapy for Poorly Controlled Type 2 Diabetes Patients
por: Lv, Wen-shan, et al.
Publicado: (2013)

Comparison of the efficacy and safety of insulin degludec/aspart (twice‐daily injections), insulin glargine 300 U/mL, and insulin glulisine (basal–bolus therapy)
por: Kawaguchi, Yuji, et al.
Publicado: (2019)

Evaluation of Glycemia Control Achieved by Glargine and Lispro Versus Detemir and Aspart Insulin Regimes in Type 2 Diabetics Undergoing Surgery
por: Ahmad, Mushtaq, et al.
Publicado: (2015)

Insulin Glargine and Acarbose in the treatment of elderly patients with diabetes
por: Li, Jing, et al.
Publicado: (2019)

Efficacy and Safety of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Treated for 26 Weeks with Multiple Daily Injections in Combination with Insulin Glargine: A Randomized Open-Label Trial (GEMELLI 1)
por: Garg, Satish K., et al.
Publicado: (2020)

Immunogenicity and Efficacy of Insulin Glargine Biosimilar Ezelin versus Originator Insulin Glargine in Patients with Type 2 Diabetes
por: Tarigan, Tri Juli Edi, et al.
Publicado: (2021)

Efficacy and safety of once‐daily insulin degludec/insulin aspart compared with once‐daily insulin glargine in participants with Type 2 diabetes: a randomized, treat‐to‐target study
por: Kumar, S., et al.
Publicado: (2016)

Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml
por: Steinstraesser, A, et al.
Publicado: (2014)

Cost of achieving HbA1c and weight loss treatment targets with IDegLira vs insulin glargine U100 plus insulin aspart in the USA
por: Billings, LK, et al.
Publicado: (2019)

Efficacy and Safety of Once-Daily Insulin Degludec/Insulin Aspart versus Insulin Glargine (U100) for 52 Weeks in Insulin-Naïve Patients with Type 2 Diabetes: A Randomized Controlled Trial
por: Kumar, Ajay, et al.
Publicado: (2016)

A case of hypersensitivity to soluble and isophane insulins but not to insulin glargine
por: Belhekar, Mahesh N., et al.
Publicado: (2015)

Efficacy and safety of LY2963016 insulin glargine in patients with type 1 and type 2 diabetes previously treated with insulin glargine
por: Hadjiyianni, I., et al.
Publicado: (2016)

Immunogenicity of LY2963016 insulin glargine and Lantus® insulin glargine in Chinese patients with type 1 or type 2 diabetes mellitus
por: Wang, Weimin, et al.
Publicado: (2022)

Safety and Effectiveness of Switching from a Basal-only to Biphasic Insulin Aspart 30 Insulin Regimen
por: Haddad, Jihad, et al.
Publicado: (2013)

Improved glycaemic control by switching from insulin NPH to insulin glargine: a retrospective observational study
por: Sharplin, Peter, et al.
Publicado: (2009)

Effects of Switching from Insulin Glargine or Detemir to Insulin Degludec in Patients with Type 1 Diabetes Mellitus
por: Kusunoki, Yoshiki, et al.
Publicado: (2013)

Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with type 1 or type 2 diabetes mellitus
por: Ilag, L. L., et al.
Publicado: (2016)

A Randomized Clinical Trial Comparing Breakfast and Bedtime Administration of Insulin Glargine in Children and Adolescents with Type 1 Diabetes
por: Gökşen Şimşek, Damla, et al.
Publicado: (2008)

Insulin Glargine: A Reevaluation of Rodent Carcinogenicity Findings
por: Stammberger, Ingo, et al.
Publicado: (2012)

A Salutary Tale—Glargine insulin and cancer risk
por: Boyle, Peter
Publicado: (2009)

Insulin-glargine/norepinephrine: Lack of efficacy: case report
Publicado: (2022)

Clinical and financial outcomes of switching insulin glargine to insulin detemir in a veteran population with type 2 diabetes
por: Asias, Bernadette D., et al.
Publicado: (2015)

Clinical Pharmacology of Fast-Acting Insulin Aspart Versus Insulin Aspart Measured as Free or Total Insulin Aspart and the Relation to Anti-Insulin Aspart Antibody Levels in Subjects with Type 1 Diabetes Mellitus
por: Haahr, Hanne, et al.
Publicado: (2018)

Cost-minimization analysis of degludec/liraglutide versus glargine/aspart: economic implications of the DUAL VII study outcomes
por: Torre, Enrico, et al.
Publicado: (2018)

Glargine insulin: an alternative to regular insulin for glycemic control in critically ill patients
por: Bhattacharyya, M, et al.
Publicado: (2007)

Insulin Detemir Versus Insulin Glargine in the Hospital: Do Hypoglycemia Rates Differ?
por: Crisher, Michelle A., et al.
Publicado: (2019)

Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial
por: Niskanen, Leo, et al.
Publicado: (2012)

Insulin degludec/insulin aspart vs biphasic insulin aspart 30 twice daily in Japanese patients with type 2 diabetes: A randomized controlled trial
por: Onishi, Yukiko, et al.
Publicado: (2016)

Insulin Glargine in the Treatment of Type 1 and Type 2 Diabetes
por: Barnett, Anthony H
Publicado: (2006)

Dose-Response Effects of Insulin Glargine in Type 2 Diabetes
por: Wang, Zhihui, et al.
Publicado: (2010)

Insulin Glargine Controversy: A Tribute to the Editorial Team at Diabetologia
por: Butler, Peter C.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_oohmndn4u1l8vdbnr1h5t66h4s